FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology, in particular to a set of antibodies for directing a radiolabeled compound in radioimmunotherapy of cancer. Also disclosed is a set of nucleic acids, a set of expression vectors and host cells for producing a set of antibodies. Invention also relates to a method of targeted radioimmunotherapy and the use of a set of antibodies in a method of directed radioimmunotherapy, as well as a method of directed transfer of a radioisotope into a tissue or organ for radioimaging.
EFFECT: invention provides targeting of radionuclides to required target cells.
97 cl, 28 dwg, 35 tbl, 11 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODIES TO CHELATED RADIONUCLIDES | 2019 |
|
RU2833233C2 |
| CRYOPRESERVED CELLS ARE NATURAL KILLERS PRELOADED WITH ANTIBODY CONSTRUCTION | 2019 |
|
RU2819927C2 |
| CELL | 2015 |
|
RU2768019C2 |
| PROTEASE-ACTIVATED T-CELL BINDING BISPECIFIC MOLECULES | 2017 |
|
RU2830288C2 |
| ISOLATED HUMAN CD45RC ANTIBODY, NUCLEIC ACID, EXPRESSION VECTOR, CELL, PHARMACEUTICAL COMPOSITION, USE THEREOF, IN VITRO METHOD OF DETECTING hCD45RC | 2019 |
|
RU2826421C2 |
| ANTI-LILRB1 ANTIBODY AND USES THEREOF | 2021 |
|
RU2813373C1 |
| HIGH-AFFINITY ANTI-PD-1 AND ANTI-LAG-3 ANTIBODIES AND BISPECIFIC BINDING PROTEINS OBTAINED FROM THEM | 2019 |
|
RU2782381C2 |
| CD131-BINDING PROTEINS AND THEIR APPLICATIONS | 2016 |
|
RU2773927C2 |
| ANTI-LILRB1 ANTIBODY AND ITS USE | 2020 |
|
RU2801535C1 |
| PROCOAGULANT ANTIBODIES | 2018 |
|
RU2810094C2 |
